"Formoterol Fumarate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ADRENERGIC BETA-2 RECEPTOR AGONIST with a prolonged duration of action. It is used to manage ASTHMA and in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
| Descriptor ID |
D000068759
|
| MeSH Number(s) |
D02.033.100.291.425 D02.092.063.291.425
|
| Concept/Terms |
Formoterol Fumarate- Formoterol Fumarate
- Formoterol Fumarate, ((R*,R*)-(+-))-isomer
- 3-Formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate
|
Below are MeSH descriptors whose meaning is more general than "Formoterol Fumarate".
Below are MeSH descriptors whose meaning is more specific than "Formoterol Fumarate".
This graph shows the total number of publications written about "Formoterol Fumarate" by people in this website by year, and whether "Formoterol Fumarate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 3 | 0 | 3 |
| 2018 | 4 | 0 | 4 |
| 2019 | 1 | 0 | 1 |
| 2020 | 3 | 1 | 4 |
| 2021 | 2 | 4 | 6 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Formoterol Fumarate" by people in Profiles.
-
Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review. Mayo Clin Proc. 2023 02; 98(2):301-315.
-
Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. Respir Med. 2022 06; 197:106857.
-
Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. Respir Med. 2021 Aug-Sep; 185:106509.
-
?2-Adrenergic receptor agonist induced hepatic steatosis in mice: modeling nonalcoholic fatty liver disease in hyperadrenergic states. Am J Physiol Endocrinol Metab. 2021 07 01; 321(1):E90-E104.
-
Reply to L?pez-Campos et al. and to Rogliani and Calzetta. Am J Respir Crit Care Med. 2021 04 01; 203(7):927-928.
-
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. Am J Respir Crit Care Med. 2021 03 01; 203(5):553-564.
-
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS. Int J Chron Obstruct Pulmon Dis. 2021; 16:179-189.
-
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial. Ther Adv Respir Dis. 2021 Jan-Dec; 15:17534666211034329.
-
Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. Respir Med. 2021 01; 176:106278.
-
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020 07 02; 383(1):35-48.